Enriched Trials May Allow Sponsors To Seek Broad Labels, FDA's Temple Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Enriching a clinical trial by selectively enrolling likely responders may nevertheless allow a sponsor to seek a broad label for the agent, Office of Drug Evaluation I Acting Director Robert Temple, MD, said during an FDA "Critical Path" update Dec. 3